Tag Archive for: antibody drug conjugates

Lonza’s Synaffix Collaborates with Qurient Therapeutics to Enable Development of Dual-Payload ADC

/in

License agreement centered around technology enabling dual-payload ADC Unique combination of Synaffix’s exatecan-based technology with Qurient’s CDK7 inhibitor Amsterdam, The Netherlands and Seongnam-Si, Korea, 25 September 2025 — Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with potential best-in-class therapeutic index, today jointly […]

Read more

Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business

/in

Clinical trial with ATAC candidate HDP-101 in multiple myeloma shows promising data Cohort 7 of the Phase I dose escalation study with HDP-101 safe and well tolerated; Cohort 8 started First patient in clinical study dosed with the second ATAC candidate HDP-102 in the non-Hodgkin lymphoma (NHL) indication Amendment of contract with HealthCare Royalty; payment of […]

Read more

Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion

/in

Licensing agreement gives Elevation Oncology access to Synaffix’s ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix’s proprietary ADC development technologies AMSTERDAM, THE NETHERLANDS, 12 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its […]

Read more

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

/in

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated […]

Read more

Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

/in

Ladenburg, Germany, 19 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the formal closing of the royalty purchase agreement with HealthCare Royalty (HCRx) for Zircaix®, signed earlier this month. Under the terms of the agreement, Heidelberg Pharma has received an upfront, non-refundable cash payment of […]

Read more